KIN

Kindred Biosciences, Inc. [KIN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

KIN Stock Summary

In the News

KIN Financial details

Company Rating
-
Market Cap
0
Income
-43.62M
Revenue
7.93M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
05 Aug 2021
P/E
-15.38
Forward P/E
-
PEG
4.61
P/S
-
P/B
5.39
P/C
-
P/FCF
-
Quick Ratio
8.56
Current Ratio
9.08
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.06
EPS next Y
-
EPS next Q
-
EPS this Y
-62.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
47.68%
EPS Q/Q
-12.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-25%
ROE
-32%
ROC
-0.22%
Gross Margin
89%
Oper. Margin
-47%
Profit Margin
-56%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.24-9.26
52W High
-
52W Low
-
RSI
-
Rel Volume
0.12
Avg Volume
1.51M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.31522
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
V
VTI
AMZ.DE
BRH.DE
VFINX
Same Sector
BAFNAPH.NS
SMSPHARMA.NS
RHK.DE
TMDX
YPSN.SW
Check Those
TY
KIRLOSBROS.NS
LXCHEM.NS
600973.SS
AIGG.L
Similar Market Cap
APPS
SJ.TO
KGH.L
TDNT
SFER.MI

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 1.51M
  • Employee 63
  • CEO Dr. Richard Chin
  • Headquarters Burlingame,CALIFORNIA,US
  • IPO Date 2013-12-12
  • Website http://www.kindredbio.com

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.